E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.
Ohad Benjamini,Hagop M. Kantarjian,Mary Beth Rios,Elias Jabbour,Susan O'Brien,Preetesh Jain,Marylou Cardenas-Turanzas,Stefan Faderl,Guillermo Garcia-Manero,Farhad Ravandi,Gautam Borthakur,Alfonso Quintás-Cardama,Jorge E. Cortes +12 more
TL;DR: Treatment discontinuation can lead to sustained CMR in some patients, but risk of relapse is higher if patients discontinue TKIs when not in CMR, and patients treated with high dose imatinib or second generation TKI had a higher cumulative proportion of sustained MMR at 12 months after discontinuation.
Journal ArticleDOI
Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines
TL;DR: Real-world evidence is provided that the prevalence of relevant comorbid conditions is substantial among CML patients in the US managed care setting and therefore needs to be considered throughout various health care decision-making processes related to CML.
Journal ArticleDOI
Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response
Qi Shen,Juan Ouyang,Guilin Tang,Elias Jabbour,Guillermo Garcia-Manero,Mark J. Routbort,Sergej Konoplev,Carlos E. Bueso-Ramos,L. Jeffrey Medeiros,Jeffrey L. Jorgensen,Sa Wang +10 more
TL;DR: Using a multicolor FCI assay, solid evidence is provided for using FCI as an ancillary test in CMML diagnosis and also, in assessment of treatment responses.
Journal ArticleDOI
Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphoma
Nicholas J. Short,Hagop M. Kantarjian,Heidi Ko,Joseph D. Khoury,Farhad Ravandi,Deborah A. Thomas,Guillermo Garcia-Manero,Maria Khouri,Jorge E. Cortes,William G. Wierda,Srdan Verstovsek,Zeev Estrov,Alessandra Ferrajoli,Philip A. Thompson,Sherry Pierce,Susan O'Brien,Elias Jabbour +16 more
TL;DR: Assistance Publique—Hô Pitaux de Paris, Hôpitaux Universitaires Henri Mondor, DHU ATVB, Service de R eanimation m edicale, Cr eteil 94000, France Universit e Paris Est Cr etil, Facult e de M edecine de Cr eeil, Institut Mondor de Recherche Biom edicalE—Groupe de recherche clinique CARMAS
Journal ArticleDOI
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD
Issa F. Khouri,Wei Wei,Martin Korbling,Francesco Turturro,Sairah Ahmed,Amin M. Alousi,Paolo Anderlini,Stefan O. Ciurea,Elias Jabbour,Betul Oran,Uday R. Popat,Gabriela Rondon,Roland L. Bassett,Alison M. Gulbis +13 more
TL;DR: The new BFR regimen is safe and effective for relapsed CLL and lymphoma patients and the 2-year overall and progression-free survival rates were 90% and 75%.